ChronoScale Corporation Common Stock (CHRN) Stock Price, News & Analysis

Company Overview

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions. These devices are utilized in hospitals and rehabilitation centers across North America and Europe, enabling physical therapists to deliver overground gait training with customizable robotic support and integrated performance tracking.

On the industrial side, EksoWorks exoskeletons—including the EksoVest and EksoZeroG—help reduce workplace fatigue and lower the risk of musculoskeletal injuries in manufacturing, warehousing and automotive assembly. By offloading weight and supporting the arms or torso, these wearable solutions improve ergonomics, enhance worker safety and boost productivity in environments that involve repetitive overhead or lifting tasks.

Ekso Bionics serves a global customer base spanning the United States, Europe and Asia. The company’s leadership team, led by Chief Executive Officer Paul R. Sandner, brings together expertise in robotics, biomechanics and healthcare to drive ongoing innovation and expand market adoption of wearable robotics technologies.

Key Stats

• Today's Range: $10.56 to $11.80
• 50-Day Range: $8.02 to $12.71
• 52-Week Range: $2.73 to $13.50
• Volume: 97,466 shs
• Average Volume: 56,049 shs
• Market Capitalization: $42.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Reduce

ChronoScale Corporation Common Stock Stock Analysis - MarketRank™

ChronoScale Corporation Common Stock scored higher than 20% of companies evaluated by MarketBeat, and ranked 783rd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

ChronoScale Corporation Common Stock has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Downside Risk

ChronoScale Corporation Common Stock has a consensus price target of $6.00, representing about 49.8% downside from its current price of $11.95.

Amount of Analyst Coverage

ChronoScale Corporation Common Stock has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ChronoScale Corporation Common Stock are expected to grow in the coming year, from ($0.10) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ChronoScale Corporation Common Stock is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ChronoScale Corporation Common Stock is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ChronoScale Corporation Common Stock has a P/B Ratio of 20.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.48% of the float of ChronoScale Corporation Common Stock has been sold short.

Short Interest Ratio / Days to Cover

ChronoScale Corporation Common Stock has a short interest ratio ("days to cover") of 2.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ChronoScale Corporation Common Stock has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ChronoScale Corporation Common Stock does not currently pay a dividend.

Dividend Growth

ChronoScale Corporation Common Stock does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for ChronoScale Corporation Common Stock this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for CHRN on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added ChronoScale Corporation Common Stock to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of ChronoScale Corporation Common Stock in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $206,642.00 in company stock, which represents 0.4857% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, ChronoScale Corporation Common Stock insiders have bought more of their company's stock than they have sold. Specifically, they have bought $206,642.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

6.90% of the stock of ChronoScale Corporation Common Stock is held by insiders.

Percentage Held by Institutions

6.42% of the stock of ChronoScale Corporation Common Stock is held by institutions.

CHRN Stock Analysis - Frequently Asked Questions

How have CHRN shares performed this year?

ChronoScale Corporation Common Stock's stock was trading at $8.64 at the beginning of 2026. Since then, CHRN stock has increased by 38.3% and is now trading at $11.95.

How were ChronoScale Corporation Common Stock's earnings last quarter?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) posted its quarterly earnings results on Tuesday, April, 28th. The company reported ($2.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $2.01. The business earned $2.14 million during the quarter, compared to analysts' expectations of $4.29 million. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative trailing twelve-month return on equity of 197.81%.

When did ChronoScale Corporation Common Stock's stock split?

ChronoScale Corporation Common Stock's stock reverse split on the morning of Monday, June 2nd 2025.The 1-15 reverse split was announced on Monday, May 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are ChronoScale Corporation Common Stock's major shareholders?

Top institutional shareholders of ChronoScale Corporation Common Stock include Roble Belko & Company Inc (0.07%). Insiders that own company stock include Daniel Asher, Scott G Davis, Steven Sherman, Jason C Jones and Jerome Wong.
View institutional ownership trends.

How do I buy shares of ChronoScale Corporation Common Stock?

Shares of CHRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ChronoScale Corporation Common Stock own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ChronoScale Corporation Common Stock investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), TransEnterix (TRXDW), Meta Platforms (META), Tesla (TSLA), Editas Medicine (EDIT) and Micron Technology (MU).

Company Calendar

• Last Earnings: 4/28/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:CHRN
• Previous Symbol: NASDAQ:EKSO
• CIK: 1549084
• Web: www.eksobionics.com
• Phone: 510-984-1761
• Fax: 510-927-2647
• Employees: 60
• Year Founded: 2005

Price Target and Rating

• Average Price Target for ChronoScale Corporation Common Stock: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: -49.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.69 million
• Net Margins: -135.66%
• Pretax Margin: -135.66%
• Return on Equity: -197.81%
• Return on Assets: -74.17%

Debt

• Debt-to-Equity Ratio: 0.25
• Current Ratio: 1.55
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $12.80 million
• Price / Sales: 3.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 20.25

Miscellaneous

• Outstanding Shares: 3,560,000
• Free Float: 3,317,000
• Market Cap: $42.54 million
• Optionable: No Data
• Beta: 0.86